| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Musculoskeletal Imaging |
1 From the Departments of Radiology (A.R., J.L.M., M.B., M.G., H.K.), Hematology (M.D., K.B.), Biostatistics (E.L.), and Pathology (P.G.), Centre Hospitalo-Universitaire Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94000 Créteil, France. Supported by the Association pour la Recherche contre le Cancer. Received June 18, 2002; revision requested August 20; final revision received March 13, 2003; accepted May 20. Address correspondence to A.R. (e-mail: alain.rahmouni@hmn.ap-hop-paris.fr).
PURPOSE: To evaluate gadolinium enhancement of bone marrow in patients with lymphoproliferative diseases and diffuse bone marrow involvement.
MATERIALS AND METHODS: Dynamic contrast material–enhanced magnetic resonance (MR) imaging of the thoracolumbar spine was performed in 42 patients with histologically proved diffuse bone marrow involvement and newly diagnosed myeloma (n = 31), non–Hodgkin lymphoma (n = 8), or Hodgkin disease (n = 3). The maximum percentage of enhancement (Emax), enhancement slope, and enhancement washout were determined from enhancement time curves (ETCs). A three-grade system for scoring bone marrow involvement was based on the percentage of neoplastic cells in bone marrow samples. Quantitative ETC values for the 42 patients were compared with ETC values for healthy subjects and with grades of bone marrow involvement by using mean t test comparisons. Receiver operating characteristic (ROC) analysis was conducted by comparing Emax values between patients with and those without bone marrow involvement. Baseline and follow-up MR imaging findings were compared in nine patients.
RESULTS: Significant differences in Emax (P < .001), slope (P < .001), and washout (P = .005) were found between subjects with normal bone marrow and patients with diffuse bone marrow involvement. ROC analysis results showed Emax values to have a diagnostic accuracy of 99%. Emax, slope, and washout values increased with increasing bone marrow involvement grade. The mean Emax increased from 339% to 737%. Contrast enhancement decreased after treatment in all six patients who responded to treatment but not in two of three patients who did not respond to treatment.
CONCLUSION: Dynamic contrast-enhanced MR images can demonstrate increased bone marrow enhancement in patients with lymphoproliferative diseases and marrow involvement.
© RSNA, 2003
Index terms: Bone marrow, MR, 321.121411, 321.121413, 321.121416, 321.12143 • Bone marrow, neoplasms, 321.342, 321.343, 321.345 • Gadolinium • Hodgkin disease, MR, 321.342 • Lymphoma, MR, 321.343 • Magnetic resonance (MR), contrast enhancement, 321.12143 • Myeloma, 321.345
This article has been cited by other articles:
|
|
 |
|
  J. Hillengass, C. Zechmann, T. Bauerle, B. Wagner-Gund, C. Heiss, A. Benner, A. Ho, K. Neben, D. Hose, H.-U. Kauczor, et al. Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation Clin. Cancer Res., May 1, 2009; 15(9): 3118 - 3125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Liu, G.-S. Huang, C.-J. Juan, M.-S. Yao, W.-P. Ho, and W. P. Chan Intervertebral Disk Degeneration Related to Reduced Vertebral Marrow Perfusion at Dynamic Contrast-Enhanced MRI Am. J. Roentgenol., April 1, 2009; 192(4): 974 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lin, A. Luciani, K. Belhadj, P. Maison, A. Vignaud, J.-F. Deux, P. Zerbib, F. Pigneur, E. Itti, H. Kobeiter, et al. Patients with Plasma Cell Disorders Examined at Whole-Body Dynamic Contrast-enhanced MR Imaging: Initial Experience Radiology, March 1, 2009; 250(3): 905 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Schaefer, C. Taverna, K. Strobel, C. Wastl, M. Kurrer, and T. F. Hany Hodgkin Disease: Diagnostic Value of FDG PET/CT after First-Line Therapy--Is Biopsy of FDG-avid Lesions Still Needed? Radiology, July 1, 2007; 244(1): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Steinbach "MRI in the Detection of Malignant Infiltration of Bone Marrow"--A Commentary Am. J. Roentgenol., June 1, 2007; 188(6): 1443 - 1445. [Full Text] [PDF]
|
|
|
|
|
|
J. Hillengass, K. Wasser, S. Delorme, F. Kiessling, C. Zechmann, A. Benner, H.-U. Kauczor, A. D. Ho, H. Goldschmidt, and T. M. Moehler Lumbar Bone Marrow Microcirculation Measurements from Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is a Predictor of Event-Free Survival in Progressive Multiple Myeloma Clin. Cancer Res., January 15, 2007; 13(2): 475 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dankerl, P. Liebisch, G. Glatting, C. Friesen, N. M. Blumstein, D. Kocot, C. Wendl, D. Bunjes, and S. N. Reske Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience Radiology, December 19, 2006; (2006) 2422051980. [Abstract] [Full Text]
|
|
|
|
|
|
L. Matuszewski, T. Persigehl, A. Wall, N. Meier, R. Bieker, H. Kooijman, B. Tombach, R. Mesters, W. E. Berdel, W. Heindel, et al. Assessment of Bone Marrow Angiogenesis in Patients with Acute Myeloid Leukemia by Using Contrast-enhanced MR Imaging with Clinically Approved Iron Oxides: Initial Experience Radiology, December 1, 2006; 242(1): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Brennan, T. Gleeson, L. E. Coate, C. Cronin, D. Carney, and S. J. Eustace A Comparison of Whole-Body MRI and CT for the Staging of Lymphoma Am. J. Roentgenol., September 1, 2005; 185(3): 711 - 716. [Abstract] [Full Text] [PDF]
|
|
